Lavipharm

Lavipharm Equity

The The Equity of Lavipharm (LAVI.AT) as of Oct 21, 2026 is 56.42 M EUR. In the previous year, The Equity was 52.98 M EUR — a change of 6.50% (higher).

Equity

56.42 MEUR

YoY

6.50%

Last updated:

In 2025, Lavipharm's equity was 56.42 M EUR, a 6.50% increase from the 52.98 M EUR equity in the previous year.

The Lavipharm Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
-19.53 M EUR
Jan 1, 2019
-14.40 M EUR
Jan 1, 2020
-12.30 M EUR
Jan 1, 2021
-9.98 M EUR
Jan 1, 2022
40.28 M EUR
Jan 1, 2023
42.74 M EUR
Jan 1, 2024
52.98 M EUR
Jan 1, 2025
56.42 M EUR
The Lavipharm Equity history
YEAREquityYoY
56.42 MEUR+6.50%
52.98 MEUR+23.96%
42.74 MEUR+6.11%
40.28 MEUR-503.75%
-9.98 MEUR-18.91%
-12.30 MEUR-14.57%
-14.40 MEUR-26.25%
-19.53 MEUR-1.96%
-19.92 MEUR-37.41%
-31.83 MEUR-11.22%
-35.85 MEUR+55.01%
-23.13 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lavipharm Stock analysis

What does Lavipharm do? Lavipharm SA manufactures and imports pharmaceuticals and veterinary products, with main categories including anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological, and gastrointestinal therapies. The company offers cosmetic products under the brands Castalia Soins Dermocosmetiques and Laviderm Active Technology for skin, face, body, scalp, and hair care. Its OTC products encompass cold and flu remedies, oral care, dermatological items, condoms, antiseptics, analgesics, laxatives, and gynecology products. The company is the parent of Lavipharm Group of Companies and previously sold HITEX, a carbon dioxide extraction subcontracting business, to Robertet SA and CODIF in January 2014. Lavipharm SA's revenue streams come from the sale of pharmaceuticals, veterinary products, cosmetics under Castalia and Laviderm, and OTC products. Pharmaceutical and veterinary products target healthcare providers and pharmacies, while cosmetics and OTC products are sold directly to consumers through retail channels. The company's brand portfolio includes Castalia Soins Dermocosmetiques, Laviderm Active Technology, and its core pharmaceutical lines, with segments defined by product categories and distribution channels. The company's primary customers are healthcare professionals and retail consumers, with pharmaceuticals distributed via pharmacies and veterinary products to animal care facilities. Cosmetic products under Castalia and Laviderm are sold to consumers for personal care, and OTC products reach consumers through general retail. The sale of HITEX to Robertet SA and CODIF in 2014 was a one-time transaction that contributed to the company's financials during that period. Lavipharm is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Lavipharm's Equity

Lavipharm's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Lavipharm's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Lavipharm's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Lavipharm's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Lavipharm’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Lavipharm stock

The Equity of Lavipharm is 56.42 M EUR in 2025.

The Equity of Lavipharm changed from 52.98 M EUR to 56.42 M EUR, representing a 6.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Lavipharm since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Lavipharm historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Lavipharm

All Key Metrics — Lavipharm